Clinical trials: Pneumococcal Vaccine
Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
The purpose of the study is to evaluate whether receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before and after CD19-targeted CAR T cell therapy will optimize cellular and humoral immunity to pneumococcus.
- Conditions
- Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL), High-grade B-cell Lymphoma (HGBCL)
- Trial name
- NCT04745559
- Testing
- Pneumococcal conjugate vaccine (PCV13), CD19 targeted CAR T Cell Therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pneumococcal Infection
Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)
The purpose of this study is to determine if revaccination with pneumococcal vaccine (PNEUMOVAX™ 23, V110) is well tolerated and produces an immune response in older Japanese adults.
- Trial name
- NCT02260882
- Testing
- PNEUMOVAX™ 23
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Obstructive Pulmonary Disease (COPD)
Seasonal Trends in Pneumococcal Carriage in COPD Patients
Patients suffering from chronic obstructive pulmonary disease (COPD) commonly get exacerbations of their illness which have many potential triggers including infection.
- Trial name
- Helios (NCT02535546)
- Where
- Ireland
- Volunteers
- 150 people
- Sponsor
- Beaumont Hospital
Pneumococcal Vaccines
Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants
The objective of the study is to evaluate the safety and tolerability of 4 injections of VAX-24 (at 3 dose levels) compared to PCV15 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant…
- Trial name
- NCT05844423
- Testing
- 0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24
- Where
- 32 sites in United States
- Volunteers
- 802 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Rheumatoid Arthritis, Spondylarthropathy
Effects of Different Antirheumatic Treatments of Arthritis on Antibody Response Following Vaccination Using Prevenar®
Previous studies have analyzed serological responses following pneumococcal vaccination using 23-valent vaccination (Pneumovax) in Rheumatoid Arthritis (RA) patients that were on different therapeutic modalities including…
- Trial name
- PVA (NCT00828997)
- Testing
- Prevenar vaccination
- Where
- Sweden
- Volunteers
- 505 people
- Sponsor
- Region Skane
Healthy Children After Vaccination
Prevenar (PCV-7) Post-Licensure Safety Study In Russia
This study is planned to monitor the local and/or systemic reactions and compatibility of PCV-7 with routine vaccines in the Russian National immunization schedule.
- Trial name
- NCT01207583
- Testing
- Non-interventional observational study
- Where
- 4 sites in Russia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infections
Immunogenicity and Reactogenicity of PCV13 Among Infants and Children in Burkina Faso
This study aims to evaluate the immunogenicity and reactogenicity of 13-valent pneumococcal conjugate vaccine among infants, toddlers and children in Bobo-Dioulasso, Burkina Faso.
- Trial name
- PCV13-Bobo (NCT01577771)
- Testing
- Prevnar13 (manufactured by Pfizer)
- Where
- 4 sites in Burkina Faso
- Volunteers
- 663 people, healthy volunteers welcome
- Sponsor
- Agence de Médecine Préventive, France
Pneumococcal Infections
A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)
The goal of this study is to evaluate the safety, tolerability, and immunogenicity of the Pneumococcal Conjugate Vaccines (PCVs) V114 and Prevnar 13™ in healthy infants switched from Prevnar 13™ to V114 during the four-dose PCV…
- Trial name
- NCT03620162
- Testing
- Prevnar 13™, V114, RotaTeq™
- Where
- 34 sites in United States, Puerto Rico and 2 more
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines
The purpose of this trial is to assess the affect of Certolizumab Pegol (CZP) treatment on antibody response to T cell-independent and T cell-dependent immunizations using pneumococcal and influenza vaccines, respectively.
- Trial name
- NCT00993668
- Testing
- Certolizumab pegol
- Where
- 41 sites in United States
- Volunteers
- 224 people
- Sponsor
- UCB Pharma
Infections, Streptococcal
Immune Memory Evaluation in Children Following a Primary Vaccination With Pneumococcal Conjugate Vaccines.
To evaluate the immunological memory against pneumococcal vaccine serotypes in children primed with conjugate vaccines by administering a booster dose of plain polysaccharide vaccine.
- Trial name
- NCT00333450
- Testing
- Pneumococcal vaccine
- Where
- 30 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Sickle Cell Disease (SCD), Invasive Bacterial Infections
Epidemiology of Invasive Bacterial Infections in Children With Sickle Cell Disease in France Between 2020 and 2025
Children with sickle cell disease are at high risk of invasive bacterial infections, which may lead to serious complications. Preventive measures, including antibiotic prophylaxis and vaccination, have changed the epidemiology of…
- Trial name
- DREPIBAC (NCT07639008)
- Where
- 31 sites in France
- Volunteers
- 350 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Prophylactic Pneumococcal Diseases
Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.
The purpose of this study is to evaluate the safety and immunogenicity of two doses of GSK Biologicals' 11 PCV vaccine when given to healthy subjects aged 18 to 40 years .
- Trial name
- NCT00327522
- Testing
- pneumococcal vaccine
- Where
- Belgium
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asplenia, β-thalassemia Major
B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals
The purpose of this study is to determine whether one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) induces immunological memory in asplenic adults and whether previously administered immunizations with the…
- Trial name
- NCT01846923
- Testing
- PCV13
- Where
- Greece
- Volunteers
- 37 people
- Sponsor
- Aghia Sophia Children's Hospital of Athens
Crohns Disease
Pneumococcal Vaccination of Crohn Patients
Inflammatory bowel disease (IBD) are at increased risk of infections. This increased susceptibility to infections is due to the disease itself, but also be-cause many patients with autoimmune conditions are treated with…
- Trial name
- PneuVAC (NCT01947010)
- Testing
- Prevenar 13, Pneumovax
- Where
- Denmark
- Volunteers
- 151 people
- Sponsor
- Statens Serum Institut
Pneumococcal Vaccines
Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam
Pneumococcus is a group of bacteria that can cause pneumonia, meningitis and other diseases. These bacteria normally live in the nose of humans and are spread from person to person by touching or sneezing.
- Trial name
- NCT01953510
- Testing
- PCV10, PCV13
- Where
- Vietnam
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Pneumococcal Immunization, Healthy Volunteers
Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether PCV21 vaccine (investigational pneumococcal conjugate vaccine) is safe and can help the body to develop germ-fighting agents called…
- Trial name
- NCT06975878
- Testing
- PCV21 vaccine, Vaxneuvance vaccine, Hexyon vaccine
- Where
- 49 sites in Belgium, Czechia and 6 more
- Volunteers
- 1,092 people, healthy volunteers welcome
- Sponsor
- Sanofi
Neisseria Meningitidis, Haemophilus Influenzae Type b
Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines
This protocol posting deals with objectives \& outcome measures of an extension phase when subjects are aged 3, 4 and 6 years of age.
- Trial name
- NCT00891176
- Testing
- MenitorixTM, Pneumococcal conjugate vaccine GSK1024850A, PrevenarTM
- Where
- 28 sites in Germany, Poland and 1 more
- Volunteers
- 582 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis, Systemic Lupus
Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease
The overall objective of this project is to study the influence of modern anti-inflammatory treatments in established inflammatory rheumatic diseases (IRD) on antibody response elicited by pneumococcal vaccination using 13-valent…
- Conditions
- Rheumatoid Arthritis, Systemic Lupus, Sjögren Syndrome, Systemic Vasculitis
- Trial name
- IPS-BOOSTER (NCT03762824)
- Testing
- 13-valent pneumococcal conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Region Skane
Asthma
Pneumococcal Vaccines in Patients With Asthma
Investigators are assessing if patients with asthma respond better to the Pneumovax vaccine if they are given Prevnar initially.
- Trial name
- NCT03260790
- Testing
- PCV13, PPSV23
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Hepatitis A
Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age
This is a study to evaluate the immunogenicity and safety of GSK Biologicals 2-dose inactivated hepatitis A vaccine when administered with a pneumococcal conjugate vaccine in children as young as 15 months of age.
- Trial name
- NCT00197002
- Testing
- GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix), Prevnar™
- Where
- 18 sites in United States
- Volunteers
- 521 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline